Colestipol adverse reactions

Revision as of 05:22, 11 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{colestipol}} {{CMG}}; {{AE}} {{SS}} ==Adverse Reactions== <div>===Gastrointestinal=== The most common adverse reactions are confined to the gastrointestinal trac...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Colestipol
COLESTID® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Colestipol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Adverse Reactions

===Gastrointestinal===

The most common adverse reactions are confined to the gastrointestinal tract. To achieve minimal GI disturbance with an optimal LDL-cholesterol lowering effect, a gradual increase of dosage starting with one dose/day is recommended. Constipation is the major single complaint and at times is severe. Most instances of Constipation are mild, transient, and controlled with standard treatment. Increased fluid intake and inclusion of additional dietary fiber should be the first step; a stool softener may be added if needed. Some patients require decreased dosage or discontinuation of therapy. Hemorrhoids may be aggravated.

Other, less frequent gastrointestinal complaints consist of abdominal discomfort (abdominal pain and cramping), intestinal gas, (bloating and flatulence), indigestion and heartburn, diarrhea and loose stools, and nausea and vomiting. Bleeding hemorrhoids and blood in the stool have been infrequently reported. Peptic ulceration, cholecystitis, and cholelithiasis have been rarely reported in patients receiving colestipol hydrochloride granules, and are not necessarily drug related.

Transient and modest elevations of aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride.

The following non-gastrointestinal adverse reactions have been reported with generally equal frequency in patients receiving COLESTID Granules, FLAVORED COLESTID Granules, or placebo in clinical studies:

Cardiovascular

Chest pain, angina, and tachycardia have been infrequently reported.

Hypersensitivity

Rash has been infrequently reported. Urticaria and dermatitis have been rarely noted in patients receiving colestipol hydrochloride granules.

Musculoskeletal

Musculoskeletal pain, aches and pains in the extremities, joint pains, arthritis, and backache have been reported.

Neurologic

Headache, migraine headache and sinus headache have been reported. Other infrequently reported complaints include dizziness, light-headedness, and [[insomnia.

Miscellaneous

Anorexia, fatigue, weakness, shortness of breath, and swelling of the hands or feet, have been infrequently reported.[1]

References

  1. "COLESTID (COLESTIPOL [[hydrochloride]]) GRANULE, FOR SUSPENSION FLAVORED COLESTID (COLESTIPOL [[hydrochloride]]) GRANULE, FOR SUSPENSION [PHARMACIA AND UPJOHN COMPANY]". Retrieved 11 February 2014. URL–wikilink conflict (help)

Template:Lipid modifying agents